Acting On Alpha-1, 4-glucosidic Bond, (e.g., Hyaluronidase, Invertase, Amylase, Etc. (some 3.2.1)) Patents (Class 435/201)
-
Publication number: 20110014649Abstract: The present invention relates to the production of an N36-binding peptide at low cost and in a large quantity utilizing a microorganism. More specifically, the present invention relates to a method for producing an N36-binding peptide comprising introducing a recombinant vector into which a DNA molecule encoding an N36-binding peptide that binds to an N36 protein derived from a retrovirus that causes immunodeficiency in a mammal has been incorporated into E. coli as a host to produce a transformant.Type: ApplicationFiled: July 26, 2007Publication date: January 20, 2011Applicant: GEKKEIKAN SAKE CO., LTD.Inventors: Hiroko Tsutsumi, Hiroki Ishida, Hiromoto Hisada, Makiko Mizumoto, Yoji Hata, Nobutaka Fujii, Masao Matsuoka, Eiichi Kodama, Shinya Oishi
-
Patent number: 7871607Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: GrantFiled: February 23, 2005Date of Patent: January 18, 2011Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Patent number: 7858339Abstract: Refractile particles containing a heterologous polypeptide as an insoluble aggregate are recovered from bacterial periplasm. The process involves culturing bacterial cells so as to express nucleic acid encoding phage lysozyme and nucleic acid encoding the heterologous polypeptide under separate promoters, disrupting the cells mechanically to release the phage lysozyme so as to release refractile particles from the bacterial cellular matrix, and recovering the released refractile particles from the periplasm. Chloroform is not used in any step and the recovery step minimizes co-recovery of cellular debris with the released refractile particles.Type: GrantFiled: October 21, 1999Date of Patent: December 28, 2010Assignee: Genentech, Inc.Inventors: Woon-Lam Susan Leung, James R. Swartz
-
Publication number: 20100323061Abstract: The present invention relates to a hybrid enzyme comprising carbohydrate-binding module amino acid sequence and a fungal alpha-amylase amino acid sequence and to a variant of a fungal wild type enzyme comprising a carbohydrate-binding module and an alpha-amylase catalytic module. The invention also relates to the use of the hybrid enzyme or the variant in starch liquefaction.Type: ApplicationFiled: August 20, 2010Publication date: December 23, 2010Applicants: Novozymes A/S, Novozymes North America, Inc.Inventors: Hiroaki Udagawa, Rikako Taira, Shinobu Takagi, Eric Allain, Carsten Hjort, Anders Vikso-Nielsen, Shiro Fukuyama, Tomoko Matsui
-
Patent number: 7855063Abstract: A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule.Type: GrantFiled: April 18, 2004Date of Patent: December 21, 2010Assignee: Yeda Research And Development Co. Ltd.Inventors: Anthony Futerman, Joel L. Sussman, Israel Silman, Michal Harel, Hay Dvir, Lilly Toker
-
Publication number: 20100311110Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius and variations thereof are provided. Further provided are methods of at least partially degrading xylotriose, xylobiose, and/or arabinofuranose-substituted xylan using isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius and variations thereof.Type: ApplicationFiled: June 15, 2010Publication date: December 9, 2010Applicant: Battelle Energy Alliance, LLCInventors: David N. Thompson, Vicki S. Thompson, Kastli D. Schaller, William A. Apel, David W. Reed, Jeffrey A. Lacey
-
Patent number: 7846431Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: GrantFiled: March 4, 2010Date of Patent: December 7, 2010Assignee: Halozyme, Inc.Inventors: Louis Bookbinder, Anirban Kundu, Gregory I. Frost
-
Publication number: 20100304405Abstract: Methods for the cell-free identification of polypeptide and polypeptide combinations with utility in biomass transformation, as well as specific novel polypeptides and cell-free systems containing polypeptide combinations discovered by such methods are disclosed.Type: ApplicationFiled: June 2, 2010Publication date: December 2, 2010Applicant: Wisconsin Alumni Research FoundationInventors: Brian G. Fox, Nathaniel L. Elsen
-
Publication number: 20100297188Abstract: The present invention concerns the preparation of purified allergens and allergoids, both derived from whole bee venom, for the desensitisation (immunotherapy) of subjects affected by a specific allergy. In particular, the present invention concerns a preparation for immunotherapy based on purified bee venom, characterised in that said bee venom is essentially mellitin-free. In addition, the preparation of a monomeric allergoid obtainable through the carbamylation or thiocarbamylation reaction of said mellitin-free bee venom, is described. Said allergoid, being characterised by reduced IgE-binding activity, may be a safer and more effective candidate for specific immunotherapy.Type: ApplicationFiled: December 16, 2008Publication date: November 25, 2010Inventors: Giovanni Mistrello, Daniela Roncarolo, Dario Zanoni, Paolo Falagiani
-
Publication number: 20100297727Abstract: The present invention provides methods for engineering proteins to optimize their performance under certain environmental conditions of interest. In some embodiments, the present invention provides methods for engineering enzymes to optimize their catalytic activity under particular environmental conditions. In some preferred embodiments, the present invention provides methods for altering the net surface charge and/or surface charge distribution of enzymes {e.g., metalloproteases or serine proteases) to obtain enzyme variants that demonstrate improved performance in detergent formulations as compared to the starting or parent enzyme.Type: ApplicationFiled: June 6, 2008Publication date: November 25, 2010Inventors: Wolfgang Aehle, Luis Gustavo Cascao-Pereira, James T. Kellis, JR., Andrew Shaw
-
Patent number: 7833771Abstract: The present invention relates to polypeptides having alpha-amylase activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to a polypeptide having carbohydrate-binding affinity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: December 5, 2007Date of Patent: November 16, 2010Assignees: Novozymes A/S, Novozymes North America IncInventors: Tine Hoff, Carsten Andersen, Tina Spendler, Sven Pedersen, Anders Vikso-Nielsen, Thomas Schafer, Jiyin Liu
-
Patent number: 7829081Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: GrantFiled: March 4, 2010Date of Patent: November 9, 2010Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Publication number: 20100279415Abstract: A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like N-glycans is provided. Also disclosed are nucleic acid sequences encoding ?-N-acetylglucosaminidases.Type: ApplicationFiled: December 12, 2008Publication date: November 4, 2010Inventors: Donald L. Jarvis, Christoph Geisler
-
Publication number: 20100273214Abstract: The present invention relates to isolated polypeptides having alpha-glucuronidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 26, 2008Publication date: October 28, 2010Applicant: Novozymes A/SInventors: Eva Hansen Holm, Dominique Aubert Skovland, Hanne Risbjerg Soerensen
-
Patent number: 7816108Abstract: The invention relates to uses of polypeptides having amylase activity, nucleic acids encoding them, and methods for making and using them. For example, in one aspect, the invention provides methods for making alcohol using polypeptides of the invention. In one aspect, the polypeptides having amylase activity have increased activity and stability at acidic, neutral and alkaline pH and increased temperature. In one aspect, the invention provides methods for producing an alcohol, for producing a high-maltose or a high-glucose syrup or a mixed syrup, for liquifying a starch-comprising composition, for hydrolyzing a starch, comprising use of polypeptides of the invention, or polypeptides encoded by the nucleic acids of this invention.Type: GrantFiled: January 9, 2007Date of Patent: October 19, 2010Assignee: Syngenta Participations AGInventors: Walter Callen, Toby Richardson, Gerhard Frey, Jay M. Short, Eric J. Mathur, Kevin A. Gray, Janne S. Kerovuo, Malgorzata Slupska
-
Publication number: 20100261232Abstract: Novel variant ?-amylase enzymes are disclosed in which the residues corresponding to R179 and G180 in Bacillus stearothermophilus (SEQ ID NO.2) are deleted. The disclosed variant ?-amylase enzymes show altered or improved stability and/or activity profiles.Type: ApplicationFiled: March 9, 2009Publication date: October 14, 2010Applicant: GENENCOR INTERNATIONAL, INC.Inventors: Eugenio Ferrari, Marc Kolkman, Craig E. Pilgrim
-
Publication number: 20100260739Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: March 9, 2010Publication date: October 14, 2010Applicant: BIOATLA, LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 7807808Abstract: The invention relates to bacteria that have increased levels of protein secretion due to genetic modification, to nucleotide sequences and gene structures containing at least one gene coding for a SecA protein having increased levels of protein secretion, to a SecA having increased levels of protein secretion, and to a method for producing desired proteins using the inventive bacteria. The invention also relates to nucleic acids coding for a SecA protein having increased levels of protein secretion, containing a SecA gene sequence or allele, a SecA homologue or derivative, or nucleotide sequences hybridising therewith and comprising at least one mutation. Surprisingly, just one mutation in a nucleotide of a SecA gene leads to increased levels of protein secretion or to protein secretion for the first time.Type: GrantFiled: November 9, 2009Date of Patent: October 5, 2010Assignee: Danisco US Inc.Inventors: Oliver Koberling, Roland Freudl
-
Publication number: 20100239559Abstract: The present invention is directed to novel food products, e.g., nutritional food products and infant formula, which contain one ore more enzymes selected from lipase, protease, and amylase that have been formulated/stabilized to have sustained stability in an aqueous medium. Such formulations are intended to provide a greater degree of compliance based on their ability to be incorporated into aqueous media while avoiding unstable breakdown of the enzyme and large overdosing due to expected breakdown when exposed to an aqueous environment, including saliva. Further described in the invention are additives packaged with instructions for combination with an aqueous medium, and instructions for the administration of the resulting mixture to a subject. In certain embodiments, enzyme insufficient patients, e.g., infants and elderly persons, would find particular benefit from the food products described herein.Type: ApplicationFiled: October 9, 2009Publication date: September 23, 2010Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Steven Freedman, Deborah A. DaSilva
-
Publication number: 20100233780Abstract: The present invention provides methods for engineering proteins to optimize their performance under certain environmental conditions of interest. In some embodiments, the present invention provides methods for engineering enzymes to optimize their catalytic activity under particular environmental conditions. In some preferred embodiments, the present invention provides methods for engineering enzymes to optimize their catalytic activity and/or stability under adverse environmental conditions. In some preferred embodiments, the present invention provides methods for engineering enzymes to optimize their storage stability, particularly under adverse environmental conditions. In some preferred embodiments, the present invention provides methods for altering the net surface charge and/or surface charge distribution of enzymes (e.g., metalloproteases) to obtain enzyme variants that demonstrate improved performance and/or stability in detergent formulations as compared to the starting or parent enzyme.Type: ApplicationFiled: June 6, 2008Publication date: September 16, 2010Inventors: Wolfgang Aehle, Luis Gustavo Cascao-Pereira, James T. Kellis, JR., Andrew Shaw
-
Publication number: 20100233783Abstract: Process for purifying a recombinant protein including one or a few procedural steps only. The process combines the step of lysis of the host cell, with the purification of the protein of interest, allowing for a rapid and much more efficient process of purification. The conditions used during the purification process are those of a high temperature and a low pH, allowing for thermostable and acid-resistant recombinant proteins to be isolated from a suspension. The invention also relates to purifying recombinant proteins which are fusion proteins, wherein one part of the protein may be selected from an enamel matrix protein, such as amelogenin.Type: ApplicationFiled: March 23, 2006Publication date: September 16, 2010Applicant: Straumann Holding AGInventors: Johan Per Henrik Svensson, Leif Bülow
-
Patent number: 7785855Abstract: The invention relates to nucleic acids encoding polypeptides having amylase activity, and methods for making and using them. In one aspect, the polypeptides having amylase activity have increased activity and stability at acidic, neutral and alkaline pH and increased temperature. In one aspect, the invention provides methods for producing an alcohol, for producing a high-maltose or a high-glucose syrup or a mixed syrup, for liquifying a starch-comprising composition, comprising use of polypeptides encoded by the nucleic acids of this invention.Type: GrantFiled: January 9, 2007Date of Patent: August 31, 2010Assignee: Syngenta Participations AGInventors: Walter Callen, Toby Richardson, Gerhard Frey, Jay M. Short, Eric J. Mathur, Kevin A. Gray, Janne S. Kerovuo, Malgorzata Slupska
-
Patent number: 7785856Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: September 12, 2007Date of Patent: August 31, 2010Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20100216213Abstract: The present invention relates to polypeptides having glucoamylase activity and isolated polynucleotides encoding said polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. The invention also relates to the composition comprising a glucoamylase of the invention as well as the use such compositions for starch conversion processes, brewing, including processes for producing fermentation products or syrups.Type: ApplicationFiled: December 10, 2009Publication date: August 26, 2010Applicants: NOVOZYMES A/S, NOVOZYMES NORTH AMERICA, INC.Inventors: Hiroaki Udagawa, Sara Landvik, Michiko Ihara, Jiyin Liu, Chee Leong Soong, Eric Allain, Shiro Fukuyama
-
Patent number: 7781201Abstract: This invention relates generally to polypeptides and peptides having an amylase activity, e.g., enzymes, polynucleotides encoding the enzymes, the use of such polypeptides and peptides. In one aspect, the polypeptides having amylase activity have increased activity and stability at acidic, neutral and alkaline pH and increased temperature. In one aspect, the invention provides methods for producing an alcohol, for producing a high-maltose or a high-glucose syrup or a mixed syrup, for liquifying a starch-comprising composition, comprising use of polypeptides having amylase activity of the invention.Type: GrantFiled: January 9, 2007Date of Patent: August 24, 2010Assignee: Syngenta Participations AGInventors: Walter Callen, Toby Richardson, Gerhard Frey, Jay M. Short, Eric J. Mathur, Kevin A. Gray, Janne S. Kerovuo, Malgorzata Slupska
-
Publication number: 20100209995Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars.Type: ApplicationFiled: February 1, 2010Publication date: August 19, 2010Applicant: VERENIUM CORPORATIONInventors: Walter Callen, Toby Richardson, Gerhard Frey, Carl Miller, Martin Kazaoka, Eric Mathur, Jay Short
-
Patent number: 7767429Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: GrantFiled: March 5, 2004Date of Patent: August 3, 2010Assignee: Halozyme, Inc.Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Publication number: 20100189707Abstract: The present invention provides stable compositions comprising a perhydrolase enzyme, a hydrogen peroxide source, and an ester substrate that efficiently generate aqueous peracid solutions. The generated peracid solutions are suitable for decontaminating and/or sanitizing a wide range of materials and equipment contaminated with pathogens or toxic chemicals. In one preferred embodiment, the stable composition comprises an acyl transferase enzyme, sodium percarbonate, and propylene glycol diacetate, and is stable for 30 days or longer. Upon addition to water, the composition is activated and generates an aqueous solution with a high ratio of peracetic acid to acetic acid.Type: ApplicationFiled: May 5, 2008Publication date: July 29, 2010Inventor: Christopher C. Barnett
-
Patent number: 7763440Abstract: The present invention provides a method for diagnosis of pre-eclampsia which comprises measuring urate in a biological sample. The sample is preferably maternal saliva.Type: GrantFiled: June 11, 2004Date of Patent: July 27, 2010Inventor: Brian David Owen Owen-Smith
-
Publication number: 20100184845Abstract: The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5- may be used to enhance the immune response to viral infection or other diseases associated with immune suppression.Type: ApplicationFiled: April 1, 2010Publication date: July 22, 2010Inventors: Gregory I. Frost, Per Borgstrom
-
Publication number: 20100184142Abstract: The invention relates to bacteria that have increased levels of protein secretion due to genetic modification, to nucleotide sequences and gene structures containing at least one gene coding for a SecA protein having increased levels of protein secretion, to a SecA having increased levels of protein secretion, and to a method for producing desired proteins using the inventive bacteria. The invention also relates to nucleic acids coding for a SecA protein having increased levels of protein secretion and containing a gene sequence SecA or an allele, homologue or derivative of said nucleotide sequences or nucleotide sequences hybridising therewith and comprising at least one mutation. Surprisingly, just one mutation in a nucleotide of a SecA gene leads to increased levels of protein secretion or to protein secretion for the first time.Type: ApplicationFiled: November 9, 2009Publication date: July 22, 2010Inventors: Oliver Koberling, Roland Freudl
-
Patent number: 7759093Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars. In one aspect, the invention provides delayed release compositions comprising an desired ingredient coated by a latex polymer coating.Type: GrantFiled: March 8, 2004Date of Patent: July 20, 2010Assignee: Verenium CorporationInventors: Walter Callen, Toby Richardson, Gerhard Frey, Kevin Gray, Janne S. Kerovuo, Malgorzata Slupska, Nelson Barton, Eileen O'Donoghue, Carl Miller
-
Publication number: 20100172892Abstract: The present invention provides a tnaluronidase. The hyaluronidase can be produced by the strain Streptomyces aitinocidm 77, Exemplary characteristics of the hyaluronidase include specific C-terminal or other amino acid sequences, including full-length sequences, and improved physico-chemical and actix itj properties as compared to known h> al?ronidase preparatkiiis. Described are also various uses of the hyaiur?nidasc, including topical administration of the h> aiuronidasc to improve skin penetration of a co-administered active substance.Type: ApplicationFiled: June 19, 2008Publication date: July 8, 2010Inventors: Tamara P. Uvarkina, Eugene G. Kahojan
-
Publication number: 20100166769Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.Type: ApplicationFiled: February 12, 2010Publication date: July 1, 2010Applicant: Academia SinicaInventors: Pei-Wen Hsiao, Chia- Ying Wu, Yi-Chun Yeh
-
Publication number: 20100159563Abstract: The present invention relates to isolated structures containing degradative enzymes produced from a marine organism. The enzymes produced are based on the carbon source upon which the marine organism is growing. The enzymes are found in structures that can be isolated such that the degradative enzymes are easily harvested.Type: ApplicationFiled: June 26, 2007Publication date: June 24, 2010Inventors: David M. Manyak, Ronald M. Weiner, Peter S. Carlson, Ernesto J. Quintero
-
Publication number: 20100143457Abstract: Soluble PH20 polypeptides are provided, including extended soluble PH20 polypeptides, and uses thereof. Also provided are other C-terminally truncated PH20 polypeptides and partially deglycosylated PH20 polypeptides and uses thereof.Type: ApplicationFiled: December 9, 2009Publication date: June 10, 2010Inventors: Ge Wei, Krishnasamy Panneer Selvam, Louis Bookbinder, Gregory I. Frost
-
Publication number: 20100120108Abstract: The present invention relates to polypeptides having glucoamylase activity and isolated polynucleotides encoding said polypeptides preferably derived from a strain of Peniphora rufomarginata. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. The invention also relates to the composition comprising a glucoamylase of the invention as well as the use such compositions for starch conversion processes, brewing, including processes for producing fermentation products or syrups.Type: ApplicationFiled: April 13, 2007Publication date: May 13, 2010Applicants: Novozymes A/S, Novozymes North America, Inc.Inventors: Sara Landvik, Jiyin Liu, Carsten Horslev Hansen, Chee Leong Soong, Jeppe Wegener Tams
-
Publication number: 20100120651Abstract: Single-dose enzyme tablets for direct sale to consumers are provided for boosting the performance of automatic laundry and dish washing operations using conventional detergents. The tablets provide a wash performance that is better than or at least equal to the wash performance of the detergents alone even when the time and or temperature of the wash cycle is decreased. The tablets may be provided in kits and the enzymes are selected to treat a variety of fabric stains as well as to provide fabric care benefits.Type: ApplicationFiled: July 11, 2006Publication date: May 13, 2010Applicant: GENENCOR INTERNATIONAL, INC.Inventors: Douglas A. Dale, David A. Estell, Beth Fryksdale, Alfred L. Gaertner, Kenneth F. Herfert, Philippe Lavielle, Janet C. Naab, Thomas Pekich
-
Publication number: 20100120091Abstract: The present invention relates to novel subtilase variants exhibiting improvements relative to the parent subtilase in one or more properties including: wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g., cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.Type: ApplicationFiled: January 15, 2010Publication date: May 13, 2010Applicant: NOVOZYMES A/SInventors: HENRIETTE DRABORG, VIBEKE SOKVGAARD NIELSEN, STEFAN MINNING
-
Publication number: 20100098794Abstract: The present invention relates to a topical anti-wrinkle and anti-aging moisturizing cream designed (formulated) to repair and restore human adult skin to its original youthful state. This has successfully been achieved by using a water based molecular mixture of high molecular weight (0.5 to 2.0 million Daltons) hyaluronic acid (HA) and of low molecular weight hyaluronic acid oligosaccharides (small HA fragments less than 12000 Daltons molecular weight) to create this unique anti-aging moisturizer. An equal mixture of high molecular HA and HA-oligosaccharides at concentrations of 0.1-0.2% was found to be essential for providing our moisturizer its unique ability to repair and rejuvenate adult human skin.Type: ApplicationFiled: October 19, 2009Publication date: April 22, 2010Inventor: Gérard Armand
-
Publication number: 20100099161Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.Type: ApplicationFiled: December 22, 2009Publication date: April 22, 2010Applicant: Novozymes A/SInventors: Thomas Thisted, Soren Kjaerulff, Carsten Andersen, Claus Crone Fuglsang
-
Publication number: 20100093034Abstract: This invention relates to an amylase derived from Bacillus horikoshii. The amylase has a preference for soluble substrates, shows substantial exo-amylase activity and has a pH optimum of about 9.8.Type: ApplicationFiled: December 10, 2009Publication date: April 15, 2010Applicant: NOVOZYMES A/SInventors: Tine Hoff, Shamkant Anant Patkar, Jeppe Wegener Tams
-
Patent number: 7695947Abstract: The present invention pertains to modified xylanase enzymes that exhibit increased thermostability and alkalophilicity, when compared with their native counterparts. Several modified xylanases exhibiting these properties are disclosed including xylanases with at least one modification at amino acid position 10, 27, 29, 75, 104, 105, 125, 129, 132, 135, 144, 157, 161, 162 or 165, or a combination thereof. Also included within the present invention is a modified xylanase that comprises at least one substituted amino acid residue and that may be characterized as having a maximum effective temperature (MET) between about 69° C. and about 78° C., wherein the modified xylanase is a Family 11 xylanase obtained from a Trichoderma sp. The present invention also includes a modified Family 11 xylanase obtained from a Trichoderma sp. characterized as having a maximum effective pH (MEP) between 5.8 and about 7.6. Modified xylanases characterized as having a MET between about 69° C. and about 78° C.Type: GrantFiled: March 17, 2006Date of Patent: April 13, 2010Assignee: National Research Council of CanadaInventor: Wing L. Sung
-
Patent number: 7695711Abstract: The invention relates to ?4,5 glycuronidase, related compositions, and methods of use thereof.Type: GrantFiled: April 11, 2006Date of Patent: April 13, 2010Assignee: Massachusetts Institute of TechnologyInventors: James R. Myette, Zachary Shriver, Ganesh Venkataraman, Ram Sasisekharan, Maitland W. McLean
-
Publication number: 20100075395Abstract: The present invention relates to a suspension culture process for producing an enzyme, comprising the steps of providing a minimal medium, which contains deionised water, mineral salts and an organic carbon source, in a vessel; inoculating the minimal medium with a fungus; incubating the minimal medium at a pH value of 1-4 for a period of time which is sufficient for the fungus to be optically visible in the minimal medium, and obtaining the enzyme, wherein the minimal medium and the vessel are not sterilised. In addition, the invention relates to an enzyme obtainable by the process according to the invention.Type: ApplicationFiled: October 29, 2007Publication date: March 25, 2010Applicant: Fachhochschule LausitzInventors: Stahmann Klaus-Peter, Susanne Nieland, Anne Wuttke
-
Patent number: 7670819Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: GrantFiled: June 8, 2007Date of Patent: March 2, 2010Assignee: Novozymes, Inc.Inventors: Paul Harris, Elizabeth Golightly
-
Patent number: 7670820Abstract: Disclosed herein are novel chitinase polypeptides and nucleic acids encoding the polypeptides. Also disclosed are related vectors, host cells, compositions, and uses.Type: GrantFiled: January 14, 2008Date of Patent: March 2, 2010Assignee: Academia SinicaInventors: Jei-Fu Shaw, Yu-Ting Chen, Lien-Hua Hsu
-
Publication number: 20100047392Abstract: The invention relates to alpha amylases and to polynucleotides and polypeptides encoding the alpha amylases. In addition, methods of using the alpha amylases are also provided. The alpha amylases have increased activity and stability at acidic, neutral and alkaline pH and at increased temperatures.Type: ApplicationFiled: September 25, 2009Publication date: February 25, 2010Applicant: Verenium CorporationInventors: Walter Callen, Toby Richardson, Gerhard Frey, Jay M. Short, Eric J. Mathur, Kevin A. Gray, Janne S. Kerovuo, Malgorzata Slupska
-
Patent number: 7666651Abstract: A polynucleotide (hpa) encoding a polypeptide having heparanase activity, vectors including same, genetically modified cells expressing heparanase, a recombinant protein having heparanase activity and antisense oligonucleotides and constructs for modulating heparanase expression.Type: GrantFiled: February 6, 2001Date of Patent: February 23, 2010Assignees: InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Iris Pecker, Israel Vlodavsky, Elena Feinstein
-
Patent number: 7666633Abstract: The invention relates to alpha amylases and to polynucleotides encoding the alpha amylases, and methods of making and using them. In addition methods of designing new alpha amylases and methods of use thereof are also provided. The alpha amylases have increased activity and stability at increased pH and temperature.Type: GrantFiled: April 6, 2006Date of Patent: February 23, 2010Inventors: Walter Callen, Toby Richardson, Gerhard Frey, Carl Miller, Martin Kazaoka, Jay M. Short, Eric J. Mathur